InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
mick Grandfathered
11/05/20 10:36 AM
profile icon
Richard2 Free
11/05/20 9:30 AM
profile icon
mick Grandfathered
04/05/20 4:08 PM
profile icon
deniseann Free
02/05/20 11:37 AM
profile icon
Richard2 Free
02/05/20 4:43 AM
profile icon
Richard2 Free
02/05/20 4:42 AM
profile icon
deniseann Free
01/30/20 12:25 PM
profile icon
lowfloatwayne Terminated
11/06/19 6:36 PM
profile icon
Richard2 Free
10/28/19 11:17 AM
profile icon
LW89 Free
08/29/19 5:42 PM
profile icon
lowfloatwayne Terminated
08/28/19 9:00 AM
profile icon
lowfloatwayne Terminated
08/26/19 9:11 PM
profile icon
cspratt15139 Free
08/18/19 8:56 AM
profile icon
lowfloatwayne Terminated
08/05/19 9:35 PM
profile icon
lowfloatwayne Terminated
07/22/19 9:48 PM
profile icon
cspratt15139 Free
06/22/19 4:18 PM
profile icon
bleu22 Free
06/16/19 3:56 PM
profile icon
cspratt15139 Free
06/15/19 8:10 PM
profile icon
420man Free
06/13/19 6:49 PM
profile icon
bleu22 Free
06/12/19 9:37 PM
profile icon
whytestocks Free
06/12/19 4:00 PM
profile icon
420man Free
06/11/19 12:11 PM
profile icon
cspratt15139 Free
06/10/19 7:30 PM
profile icon
420man Free
06/07/19 6:31 PM
profile icon
Golden Cross Free
06/02/19 4:42 AM
profile icon
whytestocks Free
05/31/19 10:30 AM
profile icon
cspratt15139 Free
05/29/19 6:56 AM
profile icon
carldfw Free
05/18/19 8:20 PM
profile icon
Golden Cross Free
05/17/19 7:10 PM
profile icon
whytestocks Free
05/06/19 9:50 AM
profile icon
Golden Cross Free
05/06/19 9:10 AM
profile icon
tknuncle Free
05/03/19 8:53 PM
profile icon
420man Free
05/03/19 7:41 PM
profile icon
pberger Free
05/03/19 7:56 AM
profile icon
ClayTrader Free
05/02/19 4:41 PM
profile icon
nokomis Free
05/02/19 10:14 AM
profile icon
pberger Free
05/02/19 9:53 AM
profile icon
Golden Cross Free
05/02/19 9:09 AM
profile icon
ClayTrader Free
05/01/19 4:57 PM
profile icon
Zarate69 Free
05/01/19 9:48 AM
profile icon
tknuncle Free
05/01/19 9:42 AM
profile icon
JJGl Free
05/01/19 8:58 AM

Hemispherx BioPharma (HEB) RSS Feed

Followers
208
Posters
912
Posts (Today)
0
Posts (Total)
15662
Created
12/05/06
Type
Free
Moderators

Hemispherx BioPharma (HEB)

Stephen Thorpe has been added as Chief Operating Officer  – HEMISPHERX BIOPHARMA INC 
Mr Thorpe with his background in Building Medical equipment and many years in production automation will be an asset to us.  Factor in his extreme devotion to dogs and  how he cannot be bullied off a life long  meat and potato diet, he has everytrhing you can ask for in a guy to lean on for technical advice and know how. 


WILLIAM CARTER – HEMISPHERX BIOPHARMA INC 

R. WILLIAM CARTER has served as Chief Scientific Officer of Hemispherx Biopharma, Inc., since May 1989, the Chairman of the company's Board of Directors since January 1992, the company's Chief Executive Officer since July 1993, the company's President since April 1995, and a Director since 1987. He is the co-inventor of Ampligen', joined the company in 1978, and from 1987 to 1988, he served as the company's Chairman. Dr. Carter was a leading innovator in the development of human interferon for a variety of treatment indications including various viral diseases and cancer. In this context, he received the first FDA approval to initiate clinical trials on a beta interferon product manufactured in the US under his supervision. From 1985 to October 1988, Dr. Carter served as the company's Chief Executive Officer and Chief Scientist. He received his MD degree from Duke University and underwent his post-doctoral training at the National Institutes of Health and Johns Hopkins University. Dr. Carter also served as Professor of Neoplastic Diseases at Hahnemann Medical University, a position he held from 1980 to 1998. He also served as Director of Clinical Research for Hahnemann Medical University's Institute for Cancer and Blood Diseases, and as a Professor at Johns Hopkins School of Medicine and the State University of New York at Buffalo. He is a Board certified physician and author of more than 200 scientific articles, including the editing of various textbooks on anti-viral and immune therapy
 

 




 


 

PIPELINE.

Commercial Products

Country:  USA
PRODUCT NAME   CATEGORY   COMMERICAL STATUS
     
Alferon N Injection®   Genital HPV (condylomata acuminata)   Sales anticipated to resume upon successful pre-approval inspection and supplemental approval by FDA
 
Country:  Argentina
PRODUCT NAME   CATEGORY   COMMERICAL STATUS
     
Alferon N Injection®   Genital HPV (condylomata acuminata)   Approved. Launch pending manufacturing approval
     
Alferon N Injection®   Refractory to Recombinant IFN   Approved. Launch pending manufacturing approval
     
Rintatolimod (U.S. Tradename: Ampligen®)   Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)   Approved. Launch pending
 
Product Candidate   Country   Indication
Ampligen®   USA   CFS/ME
     
Ampligen®   USA   HIV
     
Ampligen®   USA   Metastatic Melanoma
     
Ampligen®   USA   Renal Cell Carcinoma
     
Ampligen®   European Union   Ebola Virus Disease
     
Alferon N Injection®   European Union   MERS
 
 

 





 

 

Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
HEB Latest News
  • No Recent News Available for this company!
New Post